Summary

Triton’s analysis suggests that the Europe surgical site infection control market is estimated to progress in terms of revenue at a CAGR of 5.16% during the 2024-2032 forecast period.
The surgical site infection control market in Europe has been experiencing significant growth owing to increased awareness and stringent regulations around infection prevention. The European Centre for Disease Prevention and Control (ECDC) reports that the occurrence of surgical site infections (SSIs) ranged from 0.6% in knee prosthesis surgeries to 9.5% in open colon surgeries, depending on the type of procedure. The ECDC’s report also highlighted that European healthcare systems have been focusing on enhancing infection control measures, supported by initiatives such as the ‘Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections (EU-JAMRAI),’ which promotes best practices across EU member states.
The countries reviewed in this region comprise Germany, the Netherlands, France, Spain, Italy, the United Kingdom, and Rest of Europe.
The United Kingdom leads with the major market share, obtaining around $265.6 million in 2023
• In 17 different surgical categories,1,122 surgical site infections were identified during the hospital stay or upon readmission during 2022-2023, as per a report by the UK Health Security Agency.

• The UK has seen a concerted effort to reduce these infections, given their association with prolonged hospital stays, increased morbidity, and higher healthcare costs. These concerns drive the demand for better infection control measures, thereby contributing to the market’s growth.

• The National Health Service (NHS) and related bodies have increased funding for research into infection control technologies, including advanced wound dressings, antiseptic solutions, and surgical techniques. This pushes healthcare providers to adopt advanced SSI control products and technologies, fueling market development.
Market Forecast for Germany
The surgical site infection control market in Germany is supported by increasing awareness and stringent regulations aimed at reducing healthcare-associated infections. The nation has seen an uptick in demand for advanced infection control products, such as antimicrobial dressings, sterilization equipment, and infection-resistant surgical tools. The German Society for Hospital Hygiene has been instrumental in promoting best practices for infection prevention. This focus on infection control is reflected in the German healthcare sector’s increased investment in modern technologies and training programs designed to minimize the risk of SSIs, enhancing overall patient safety and surgical outcomes.
The market is branched into type of infection, procedure, industry vertical, and product. Based on the type of infection, it is divided into superficial, deep incisional, and organ or space SSI.
Surgical site infections (SSIs) are a common complication in gastrointestinal surgeries, particularly influenced by the type of surgery and wound closure methods used. Among these, superficial incisional SSIs are the most frequent, occurring at the incision site on the skin and often leading to pus formation. They can be classified into two types: primary, which occurs at the main incision site, such as in a C-section, and secondary, which arises at an additional incision site, like a donor site in coronary artery bypass graft surgery.
Contender Analysis in the Surgical Site Infection Control Market:
BioMérieux SA offers a range of solutions and products for diagnosing and managing infectious diseases, cardiovascular conditions, and specific cancers. Its services also include microbial flora analysis, detection of pathogenic bacteria, air and surface quality monitoring, etc. In the healthcare sector, it supports medical clinics, hospitals, pharmaceutical companies, dental and orthodontic professionals, and health information systems. The company operates through subsidiaries and an extensive network of distributors. It is headquartered in Marcy l’Étoile, France.
In January 2024, the company acquired LUMED, a software firm specializing in clinical decision support systems. LUMED’s technology assists hospitals in optimizing antimicrobial prescriptions and tracking healthcare-associated infections.
Other major companies in the market are 3M, Ansell Limited, Johnson & Johnson, Kimberly-Clark Corporation, and Stryker Corporation.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1. EUROPE SURGICAL SITE INFECTION CONTROL MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. IMPACT ANALYSIS ON THE SURGICAL SITE INFECTION CONTROL MARKET
2.1.1. COVID-19 IMPACT
2.2. PORTER’S FIVE FORCES ANALYSIS
2.2.1. THREAT OF NEW ENTRANTS
2.2.2. THREAT OF SUBSTITUTES
2.2.3. BARGAINING POWER OF BUYERS
2.2.4. BARGAINING POWER OF SUPPLIERS
2.2.5. THREAT OF COMPETITIVE RIVALRY
2.3. KEY MARKET STRATEGIES
2.3.1. PRODUCT LAUNCHES
2.3.2. ACQUISITIONS
2.3.3. BUSINESS DIVESTITURES & EXPANSIONS
2.4. MARKET DRIVERS
2.4.1. ESCALATING INCIDENCE OF HOSPITAL-ACQUIRED INFECTIONS
2.4.2. GROWING GERIATRIC POPULATION
2.4.3. REGULATORY GUIDELINES FOR PREVENTING HOSPITAL-ACQUIRED INFECTION
2.5. MARKET CHALLENGES
2.5.1. INCREASE IN OUTPATIENT TREATMENT
2.5.2. SURGE IN MEDICAL WASTE DUE TO THE USE OF DISPOSABLE MEDICAL ITEMS
2.5.3. INSUFFICIENT AWARENESS REGARDING HOSPITAL-ACQUIRED INFECTIONS
2.6. MARKET OPPORTUNITIES
2.6.1. GROWTH OF MINIMALLY INVASIVE AND OUTPATIENT SURGICAL PRACTICES
2.6.2. RISE IN SURGICAL PROCEDURE RATES
2.6.3. TECHNOLOGICAL ADVANCEMENTS IN PREVENTING SURGICAL SITE INFECTIONS
2.7. ANALYST PERSPECTIVE
3. EUROPE SURGICAL SITE INFECTION CONTROL MARKET – BY PROCEDURE
3.1. LAPAROSCOPY
3.2. ORTHOPEDIC SURGERY
3.3. CARDIOVASCULAR
3.4. OBSTETRICS AND GYNECOLOGY
3.5. WOUND CLOSURE
3.6. PLASTIC & RECONSTRUCTIVE SURGERY
3.7. THORACIC SURGERY
3.8. MICROVASCULAR
3.9. UROLOGY
3.10. NEUROSURGERY
3.11. OTHER PROCEDURES
4. EUROPE SURGICAL SITE INFECTION CONTROL MARKET – BY TYPE OF INFECTION
4.1. SUPERFICIAL INCISIONAL SSI
4.2. DEEP INCISIONAL SSI
4.3. ORGAN OR SPACE SSI
5. EUROPE SURGICAL SITE INFECTION CONTROL MARKET – BY INDUSTRY VERTICAL
5.1. HOSPITALS
5.2. AMBULATORY SURGICAL CENTERS
6. EUROPE SURGICAL SITE INFECTION CONTROL MARKET – BY PRODUCT
6.1. DISINFECTANTS
6.1.1. SKIN DISINFECTANTS
6.1.2. HAND DISINFECTANTS
6.2. MANUAL REPROCESSORS SOLUTIONS
6.3. SURGICAL DRAPES
6.4. SURGICAL GLOVES
6.5. SKIN PREPARATION SOLUTIONS
6.6. SURGICAL IRRIGATION
6.7. SURGICAL SCRUBS
6.8. HAIR CLIPPERS
6.9. MEDICAL NONWOVENS
6.10. OTHER PRODUCTS
7. EUROPE SURGICAL SITE INFECTION CONTROL MARKET – BY COUNTRY OUTLOOK
7.1. EUROPE
7.1.1. COUNTRY ANALYSIS
7.1.1.1. UNITED KINGDOM
7.1.1.1.1. UNITED KINGDOM SURGICAL SITE INFECTION CONTROL MARKET FORECAST & PROSPECTS
7.1.1.2. GERMANY
7.1.1.2.1. GERMANY SURGICAL SITE INFECTION CONTROL MARKET FORECAST & PROSPECTS
7.1.1.3. FRANCE
7.1.1.3.1. FRANCE SURGICAL SITE INFECTION CONTROL MARKET FORECAST & PROSPECTS
7.1.1.4. SPAIN
7.1.1.4.1. SPAIN SURGICAL SITE INFECTION CONTROL MARKET FORECAST & PROSPECTS
7.1.1.5. ITALY
7.1.1.5.1. ITALY SURGICAL SITE INFECTION CONTROL MARKET FORECAST & PROSPECTS
7.1.1.6. THE NETHERLANDS
7.1.1.6.1. THE NETHERLANDS SURGICAL SITE INFECTION CONTROL MARKET FORECAST & PROSPECTS
7.1.1.7. REST OF EUROPE
7.1.1.7.1. REST OF EUROPE SURGICAL SITE INFECTION CONTROL MARKET FORECAST & PROSPECTS
8. COMPETITIVE LANDSCAPE
8.1. AMERICAN POLYFILM INC
8.1.1. OVERVIEW
8.1.2. PORTFOLIO
8.1.3. KEY STRENGTHS
8.1.4. KEY CHALLENGES
8.2. 3M
8.2.1. OVERVIEW
8.2.2. PORTFOLIO
8.2.3. KEY STRENGTHS
8.2.4. KEY CHALLENGES
8.3. ANSELL LIMITED
8.3.1. OVERVIEW
8.3.2. PORTFOLIO
8.3.3. KEY STRENGTHS
8.3.4. KEY CHALLENGES
8.4. BELIMED LIFE SCIENCE AG
8.4.1. OVERVIEW
8.4.2. PORTFOLIO
8.4.3. KEY STRENGTHS
8.4.4. KEY CHALLENGES
8.5. BECTON, DICKINSON AND COMPANY (BD)
8.5.1. OVERVIEW
8.5.2. PORTFOLIO
8.5.3. KEY STRENGTHS
8.5.4. KEY CHALLENGES
8.6. BIOMERIEUX SA
8.6.1. OVERVIEW
8.6.2. PORTFOLIO
8.6.3. KEY STRENGTHS
8.6.4. KEY CHALLENGES
8.7. GETINGE AB
8.7.1. OVERVIEW
8.7.2. PORTFOLIO
8.7.3. KEY STRENGTHS
8.7.4. KEY CHALLENGES
8.8. GAMA HEALTHCARE
8.8.1. OVERVIEW
8.8.2. PORTFOLIO
8.8.3. KEY STRENGTHS
8.8.4. KEY CHALLENGES
8.9. JOHNSON & JOHNSON
8.9.1. OVERVIEW
8.9.2. PORTFOLIO
8.9.3. KEY STRENGTHS
8.9.4. KEY CHALLENGES
8.10. SOTERA HEALTH LLC
8.10.1. OVERVIEW
8.10.2. PORTFOLIO
8.10.3. KEY STRENGTHS
8.10.4. KEY CHALLENGES
8.11. KIMBERLY-CLARK CORPORATION
8.11.1. OVERVIEW
8.11.2. PORTFOLIO
8.11.3. KEY STRENGTHS
8.11.4. KEY CHALLENGES
8.12. STERIS CORPORATION
8.12.1. OVERVIEW
8.12.2. PORTFOLIO
8.12.3. KEY STRENGTHS
8.12.4. KEY CHALLENGES
8.13. STRYKER CORPORATION
8.13.1. OVERVIEW
8.13.2. PORTFOLIO
8.13.3. KEY STRENGTHS
8.13.4. KEY CHALLENGES
9. RESEARCH METHODOLOGY & SCOPE
9.1. RESEARCH SCOPE & DELIVERABLES
9.2. SOURCES OF DATA
9.3. RESEARCH METHODOLOGY


LIST OF TABLES
TABLE 1: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY COUNTRY OUTLOOK, 2024-2032 (IN $ MILLION)
TABLE 2: LIST OF PRODUCT LAUNCHES
TABLE 3: LIST OF ACQUISITIONS
TABLE 4: LIST OF BUSINESS DIVESTITURES & EXPANSIONS
TABLE 5: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY PROCEDURE, 2024-2032 (IN $ MILLION)
TABLE 6: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY TYPE OF INFECTION, 2024-2032 (IN $ MILLION)
TABLE 7: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY INDUSTRY VERTICAL, 2024-2032 (IN $ MILLION)
TABLE 8: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY PRODUCT, 2024-2032 (IN $ MILLION)
TABLE 9: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY COUNTRY OUTLOOK, 2024-2032 (IN $ MILLION)

LIST OF FIGURES
FIGURE 1: PORTER’S FIVE FORCES ANALYSIS
FIGURE 2: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY PROCEDURE, 2023 & 2032 (IN %)
FIGURE 3: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY LAPAROSCOPY, 2024-2032 (IN $ MILLION)
FIGURE 4: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY ORTHOPEDIC SURGERY, 2024-2032 (IN $ MILLION)
FIGURE 5: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY CARDIOVASCULAR, 2024-2032 (IN $ MILLION)
FIGURE 6: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY OBSTETRICS AND GYNECOLOGY, 2024-2032 (IN $ MILLION)
FIGURE 7: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY WOUND CLOSURE, 2024-2032 (IN $ MILLION)
FIGURE 8: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY PLASTIC & RECONSTRUCTIVE SURGERY, 2024-2032 (IN $ MILLION)
FIGURE 9: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY THORACIC SURGERY, 2024-2032 (IN $ MILLION)
FIGURE 10: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY MICROVASCULAR, 2024-2032 (IN $ MILLION)
FIGURE 11: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY UROLOGY, 2024-2032 (IN $ MILLION)
FIGURE 12: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY NEUROSURGERY, 2024-2032 (IN $ MILLION)
FIGURE 13: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY OTHER PROCEDURES, 2024-2032 (IN $ MILLION)
FIGURE 14: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY TYPE OF INFECTION, 2023 & 2032 (IN %)
FIGURE 15: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY SUPERFICIAL INCISIONAL SSI, 2024-2032 (IN $ MILLION)
FIGURE 16: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY DEEP INCISIONAL SSI, 2024-2032 (IN $ MILLION)
FIGURE 17: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY ORGAN OR SPACE SSI, 2024-2032 (IN $ MILLION)
FIGURE 18: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY INDUSTRY VERTICAL, 2023 & 2032 (IN %)
FIGURE 19: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY HOSPITALS, 2024-2032 (IN $ MILLION)
FIGURE 20: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY AMBULATORY SURGICAL CENTERS, 2024-2032 (IN $ MILLION)
FIGURE 21: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY PRODUCT, 2023 & 2032 (IN %)
FIGURE 22: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY DISINFECTANTS, 2024-2032 (IN $ MILLION)
FIGURE 23: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY DISINFECTANTS, 2023 & 2032 (IN %)
FIGURE 24: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY SKIN DISINFECTANTS, 2024-2032 (IN $ MILLION)
FIGURE 25: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY HAND DISINFECTANTS, 2024-2032 (IN $ MILLION)
FIGURE 26: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY MANUAL REPROCESSORS SOLUTIONS, 2024-2032 (IN $ MILLION)
FIGURE 27: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY SURGICAL DRAPES, 2024-2032 (IN $ MILLION)
FIGURE 28: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY SURGICAL GLOVES, 2024-2032 (IN $ MILLION)
FIGURE 29: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY SKIN PREPARATION SOLUTIONS, 2024-2032 (IN $ MILLION)
FIGURE 30: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY SURGICAL IRRIGATION, 2024-2032 (IN $ MILLION)
FIGURE 31: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY SURGICAL SCRUBS, 2024-2032 (IN $ MILLION)
FIGURE 32: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY HAIR CLIPPERS, 2024-2032 (IN $ MILLION)
FIGURE 33: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY MEDICAL NONWOVENS, 2024-2032 (IN $ MILLION)
FIGURE 34: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY OTHER PRODUCTS, 2024-2032 (IN $ MILLION)
FIGURE 35: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY COUNTRY OUTLOOK, 2023 & 2032 (IN %)
FIGURE 36: UNITED KINGDOM SURGICAL SITE INFECTION CONTROL MARKET 2024-2032 (IN $ MILLION)
FIGURE 37: GERMANY SURGICAL SITE INFECTION CONTROL MARKET 2024-2032 (IN $ MILLION)
FIGURE 38: FRANCE SURGICAL SITE INFECTION CONTROL MARKET 2024-2032 (IN $ MILLION)
FIGURE 39: ITALY SURGICAL SITE INFECTION CONTROL MARKET 2024-2032 (IN $ MILLION)
FIGURE 40: SPAIN SURGICAL SITE INFECTION CONTROL MARKET 2024-2032 (IN $ MILLION)
FIGURE 41: THE NETHERLANDS SURGICAL SITE INFECTION CONTROL MARKET 2024-2032 (IN $ MILLION)
FIGURE 42: REST OF EUROPE SURGICAL SITE INFECTION CONTROL MARKET 2024-2032 (IN $ MILLION)